Innovotech Inc. (TSX Venture Exchange: IOT; OTCQB: IOTCF) announced its financial results for the first quarter ended March 31, 2026, revealing a significant revenue decline attributed to changes in a large project for a major customer. Revenue for the quarter was $648,140, down 44% from $1,158,000 in Q1 2025. The company had previously expected the project to continue through 2026, but the customer altered its activities, leading to the shortfall.
Gross profit fell to $202,231, with a gross margin of 31.2% compared to 53.6% in the prior year. The margin compression resulted from underutilized capacity, as Innovotech maintained staffing and operational readiness in anticipation of the planned customer work. The company recorded a net loss of $401,295, a sharp reversal from net income of $63,523 in Q1 2025. Operating expenses increased year over year, reflecting the integration of Keystone Labs and Innovotech Labs, relocation of Keystone Labs operations, and investments in a stronger sales organization.
Despite the quarterly loss, Innovotech continues to advance its strategic transformation. The company strengthened its leadership and commercial teams and completed its OTCQB listing in the U.S. Innovotech maintains a strong liquidity position and a meaningful equity base, providing flexibility to manage near-term volatility while executing its long-term strategy. CEO Craig Milne stated, “Management remains committed to investing in a more diversified, resilient, and scalable platform. The Company is continuing to execute its transformation strategy with a focus on the operational and commercial initiatives required to support long-term growth and reduce revenue concentration risk.”
The company’s reliance on a small number of customers has been a recurring risk factor, as highlighted in its forward-looking statements. The Q1 results underscore the impact of client concentration, with the loss of a major project causing a substantial revenue decline. Innovotech’s management is actively working to expand service offerings and generate consistent recurring revenue to mitigate this risk. The company operates through ISO-certified and GMP-accredited laboratories, providing contract research, analytical, and microbial testing services to medical device, pharmaceutical, and industrial clients. Its proprietary MBEC Assay® platform is widely used for high-throughput antimicrobial and antibiotic testing.
Innovotech’s unaudited consolidated financial statements and Management’s Discussion and Analysis have been filed on SEDAR+ and the OTCIQ. The company’s full press release is available at NewMediaWire. For more information about Innovotech, visit Innovotech.ca.